|Infectious Diseases Summit|
Antiviral Drugs Research & Development
Vaccines Research & Development
Anti-Infectives Partnering & Deal-Making
Innovative approaches in the development of antiviral drugs is crucial for improvements of current therapies and possible new indications. Continually emerging global viral threats along with antiviral resistance and viral immune evasion pose a significant challenge to current antivirals. Increased awareness and understanding in these areas aid our progress towards better treatment regimens.
Leaders in industry and academia will discuss current landscape and emerging new therapies in the field of HIV, RSV, Hepatitis B/C, Influenza etc. New drug designs and their mechanism of actions, approaches to address immune evasion mechanisms and viral resistance, and challenges in clinical study designs will also be discussed. We invite you to attend and engage with other prominent thinkers in the field on July 13-14, 2017 in Baltimore, MD.
- Plenary Session: Responding to Emerging Infectious Diseases on the Global Stage
- Respiratory Viral Infections: Current Landscape and Emerging Drugs
- Blood Borne Pathogens: New Frontiers in Research and Drug Development
- Challenges in Clinical Study Design and Considerations
- Panel: New Approaches to Antiviral Development
- General Session: Public/Private Partnerships in Support of Global Health
We hope to see you there!
The 2017 Advisory Committee
|2017 Program Director|
|Rupa Challa, Spring Bank Pharmaceuticals|
|2017 Advisory Board Members|
|Tara Strutt, University of Central Florida|
|Nafija Serdarevic, University of Sarajevo|
|Kris Iyer, Spring Bank Pharmaceuticals|
|Kai Mckinstry, University of Central Florida|
|Kevin Gilligan, ClinicalRM|
|Seshadri Vasan, Public Health England & University of York|
|Priscilla Yang, Harvard Medical School|
|Nicholas Meanwell, Bristol-Myers Squibb|
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
Viracor Eurofins provides clinical trial biomarker testing services with expertise in custom assay transfer, design and validation for phase I-IV trials. Our CAP/CLIA and NY state accredited laboratory has over 30 years of experience in molecular testing, immune response monitoring, vaccine safety/efficacy assessment, allergy and hypersensitivity testing.